Bristol-Myers Squibb Company (BMY) EVP Thomas J. Jr. Lynch Sells 5,300 Shares of Stock
Bristol-Myers Squibb Company (NYSE:BMY) EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up $0.28 on Friday, hitting $62.41. The company had a trading volume of 8,083,762 shares, compared to its average volume of 8,352,112. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $103,881.36, a P/E ratio of 21.44, a price-to-earnings-growth ratio of 2.41 and a beta of 1.18. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Tradewinds Capital Management LLC increased its position in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb in the second quarter worth $111,000. Massey Quick Simon & CO. LLC increased its position in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. Proficio Capital Partners LLC increased its position in Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. Finally, American National Bank increased its position in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares during the last quarter. 69.82% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on BMY shares. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 target price on the stock in a report on Thursday, August 17th. Jefferies Group restated a “buy” rating and issued a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. BMO Capital Markets restated a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Goldman Sachs Group restated a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Finally, Credit Suisse Group restated a “hold” rating on shares of Bristol-Myers Squibb in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $64.93.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.